A bolus of inhaled budesonide rapidly reverses airway subsensitivity and β2-adrenoceptor down-regulation after regular inhaled formoterol

Chest

Volumn 115, Issue 3, 1999, Pages 623-628

  Aziz, Imran ^a   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Adenosine monophosphate; Bronchoconstriction; Budesonide; Formoterol; Subsensitivity; 2 adrenoceptor

Indexed keywords

ADENOSINE PHOSPHATE; BETA 2 ADRENERGIC RECEPTOR; BUDESONIDE; FORMOTEROL; FORMOTEROL FUMARATE;

ADULT; ARTICLE; ASTHMA; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROSSOVER PROCEDURE; DNA POLYMORPHISM; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; RECEPTOR SENSITIVITY;

EID: 0033064613     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.115.3.623     Document Type: Article

References (28)

1. 1 National Asthma Education and Prevention Program. Expert panel report II: guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health, publication No. 97-4051, 1997
2. 2 British Thoracic Society. Guidelines on the management of asthma. Thorax 1997; 52:S1-S21
3. 3 Yates DH, Sussman HS, Shaw MJ, et al. Regular formoterol treatment in mild asthma: effect on bronchial responsiveness during and after treatment. Am J Respir Crit Care Med 1995; 152:1170-1174
4. 4 Cheung D, Timmers MC, Zwinderman AH, et al. Long-term effects of long-acting beta-2 adrenoceptor agonist salmeterol on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992; 327:1198-1203
5. 5 Ramage L, Lipworth BJ, Ingram CG, et al. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994; 88:363-368
6. 6 Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995; 346:201-206
7. 7 Newnham DM, McDevitt DG, Lipworth BJ. Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. Am J Med 1994; 97:29-37
8. 2-Adrenoceptor polymorphism is associated with susceptibility to bronchodilator desensitization in moderately severe stable asthmatics. Lancet 1997; 350:995-999
9. 9 Tan KS, Grove A, McLean A, et al. Systemic corticosteroid rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am J Respir Crit Care Med 1997; 156:28-35
10. 10 Polosa R, Holgate ST. Adenosine bronchoconstriction: a promising marker of allergic inflammation in asthma. Thorax 1997; 52:919-923
11. 11 American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136:225-244
12. 12 Tan KS, McFarlane LC, Lipworth BJ. Modulation of airway reactivity and peak flow variability in asthmatics receiving the oral contraceptive pill. Am J Respir Crit Care Med 1997; 155:1273-1277
13. 13 Egbagbe E, Pavord ID, Wilding P, et al. Adenosine monophosphate and histamine induced bronchoconstriction: repeatability and protection by terbutaline. Thorax 1997; 52: 239-243
14. 2-adrenoceptor polymorphism with lower airways reactivity in asthmatic subjects. Lancet 1997; 345:1213-1214
15. 15 Lipworth B, Tan S, Devlin M, et al. Effects of treatment with formoterol on bronchoprotection against methacholine. Am J Med 1998; 104:431-438
16. 16 McIvor RA, Pizzichini E, Turner MO, et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998; 158:924-930
17. 17 Hadcock JR, Williams DL, Malbon CC. Physiological regulation at the level of mRNA: analysis of steady-state of specific mRNAs by DNA-excess solution hybridization. Am J Physiol 1989; 256:C457-C465
18. 18 Pansegrouw DF. Acute resistant asthma caused by excessive beta-2 adrenoceptor agonist inhalation and reversed by inhalation of beclomethasone. S Afr Med J 1992; 82:179-182
19. 19 Gibson PG, Saltos N, Carty K, et al. Acute effect of budesonide on airway eosinophils and airway responsiveness in asthma. Am J Respir Crit Care Med 1997; 155(pt 2):A289
20. 20 O'Connor BJ, Ridge SM, Barnes PJ, et al. Greater effect of inhaled budesonide on adenosine 5-monophosphate, induced then on sodium metabisulphite induced bronchoconstriction in asthma. Am Rev Respir Dis 1992; 146:560-564
21. 2-adrenergic tolerance in mild asthma. Thorax 1998; 53:110-113
22. 22 Hauck RW, Bohm M, Gengenbach S, et al. Beta-2-adrenoceptors in human lung and peripheral mononuclear leukocytes of untreated and terbutaline treated patients. Chest 1990; 98:376-381
23. 23 Hayes MJ, Quing F, Rhodes CG, et al. In-vivo quantification of human pulmonary β-adrenoceptors effect of β-agonist therapy. Am J Respir Crit Care Med 1996; 154:1277-1283
24. 24 Thorsson L, Edsbacker S, Conradson T-B. Lung deposition of budesonide from Turbohaler is twice that from pressurized metered dose inhaler. Eur Respir J 1994; 7:1839-1844
25. 25 Lonnebo A, Grahnen A, Jansson B, et al. An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers. Eur J Clin Pharmacol 1996; 49:459-463
26. 26 Thorsson L, Dahlstron K, Edsbacker S, et al. Pharmacokinetic and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1997; 43:155-161
27. 2-adrenoceptor function in asthmatic patients. Chest 1996; 109:343-347
28. 28 Rodrigo G, Rodrigo C. Inhaled flunisolide for acute severe asthma. Am J Respir Crit Care Med 1998; 157:698-703